Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Novartis AG ADR

Healthcare US NVS

161.59USD
-1.2(0.74%)

Last update at 2026-03-10T20:14:00Z

Day Range

160.43163.07
LowHigh

52 Week Range

79.64105.61
LowHigh

Fundamentals

  • Previous Close 162.79
  • Market Cap202976.67M
  • Volume3694409
  • P/E Ratio25.58
  • Dividend Yield3.54%
  • EBITDA21593.00M
  • Revenue TTM54217.00M
  • Revenue Per Share TTM25.84
  • Gross Profit TTM 36744.00M
  • Diluted EPS TTM3.86

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 8371.00M 26137.00M 9878.00M 8940.00M 13835.00M
Minority interest 0.00000M 3.00M 68.00M 77.00M 78.00M
Net income 6955.00M 24021.00M 8072.00M 7147.00M 12611.00M
Selling general administrative 14253.00M 14815.00M 14197.00M 14369.00M 16471.00M
Selling and marketing expenses - - - - -
Gross profit 36342.00M 37010.00M 34777.00M 34252.00M 34759.00M
Reconciled depreciation 7181.00M 6113.00M 6464.00M 5826.00M 6892.00M
Ebit 9197.00M 26948.00M 10152.00M 9086.00M 14858.00M
Ebitda 16389.00M 33061.00M 17211.00M 15616.00M 21750.00M
Depreciation and amortization 7192.00M 6113.00M 7059.00M 6530.00M 6892.00M
Non operating income net other - - - - -
Operating income 9197.00M 26948.00M 10152.00M 9086.00M 8169.00M
Other operating expenses 42631.00M 41188.00M 39746.00M 39591.00M 44997.00M
Interest expense 837.00M 811.00M 869.00M 850.00M 957.00M
Tax provision 1416.00M 2119.00M 1807.00M 1793.00M 1295.00M
Interest income 379.00M 14628.00M 91.00M 36.00M 5.00M
Net interest income -633.00000M -891.00000M -947.00000M -645.00000M -706.00000M
Extraordinary items - - - 4590.00M -186.00000M
Non recurring - - - - -
Other items - - - - -
Income tax expense 1416.00M 2119.00M 1807.00M 1793.00M 1221.00M
Total revenue 51828.00M 52877.00M 49898.00M 48677.00M 53166.00M
Total operating expenses 27145.00M 25321.00M 24625.00M 25166.00M 26590.00M
Cost of revenue 15486.00M 15867.00M 15121.00M 14425.00M 18407.00M
Total other income expense net -826.00000M -811.00000M -274.00000M -146.00000M 6372.00M
Discontinued operations - - - 4590.00M -186.00000M
Net income from continuing ops 6955.00M 24018.00M 8071.00M 7147.00M 12614.00M
Net income applicable to common shares 6955.00M 24021.00M 8072.00M 11732.00M 12611.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 117453.00M 131795.00M 132059.00M 118370.00M 145563.00M
Intangible assets 31644.00M 34182.00M 36809.00M 28787.00M 38719.00M
Earning assets - - - - -
Other current assets 2471.00M 2440.00M 2523.00M 2680.00M 1619.00M
Total liab 58030.00M 63973.00M 75393.00M 62819.00M 66871.00M
Total stockholder equity 59342.00M 67655.00M 56598.00M 55474.00M 78614.00M
Deferred long term liab 4421.00M 5499.00M 4700.00M 5424.00M 15047.00M
Other current liab 17205.00M 17962.00M 17529.00M 15449.00M 14195.00M
Common stock 890.00M 901.00M 913.00M 936.00M 944.00M
Capital stock 890.00M 901.00M 913.00M 936.00M 944.00M
Retained earnings 63540.00M 70989.00M 57157.00M 59275.00M 82191.00M
Other liab 7592.00M 9242.00M 14356.00M 12499.00M 14794.00M
Good will 29301.00M 29595.00M 29999.00M 26524.00M 35294.00M
Other assets 4849.00M 12425.00M 14728.00M 14799.00M 25549.00M
Cash 7517.00M 12407.00M 9658.00M 11112.00M 13271.00M
Cash and equivalents 4640.00M 9011.00M 5908.00M 7865.00M 10150.00M
Total current liabilities 28656.00M 30208.00M 33059.00M 28264.00M 29607.00M
Current deferred revenue 123.00M 123.00M 56.00M 114.00M 236.00M
Net debt 20447.00M 18686.00M 28391.00M 18221.00M 18819.00M
Short term debt 6182.00M 6570.00M 10071.00M 7277.00M 9620.00M
Short long term debt 5876.00M 6227.00M 9591.00M 6846.00M 9620.00M
Short long term debt total 27964.00M 31093.00M 38049.00M 29333.00M 32090.00M
Other stockholder equity -92.00000M -48.00000M -53.00000M -80.00000M -69.00000M
Property plant equipment 12195.00M 13106.00M 13939.00M 13746.00M 15696.00M
Total current assets 36910.00M 45718.00M 29673.00M 29504.00M 35563.00M
Long term investments 1606.00M 2268.00M 11700.00M 11162.00M 10697.00M
Net tangible assets 2818.00M 9377.00M -5510.00000M 5587.00M 19648.00M
Short term investments 11413.00M 15922.00M 1905.00M 334.00M 2693.00M
Net receivables 8334.00M 8283.00M 8456.00M 8555.00M 11024.00M
Long term debt 20244.00M 22902.00M 26259.00M 20353.00M 22470.00M
Inventory 7175.00M 6666.00M 7131.00M 5982.00M 6956.00M
Accounts payable 5146.00M 5553.00M 5403.00M 5424.00M 5556.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 58544.00M 66802.00M 55738.00M 54618.00M 77739.00M
Additional paid in capital - - - - -
Common stock total equity - - 913.00M 936.00M 944.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - -48.00000M -53.00000M -80.00000M -69.00000M
Accumulated amortization - - - - -
Non currrent assets other 1110.00M 2210.00M 892.00M 738.00M 895.00M
Deferred long term asset charges - - - - -
Non current assets total 80543.00M 86077.00M 102386.00M 88866.00M 110000.00M
Capital lease obligations 1789.00M 1896.00M 2005.00M 1949.00M -
Long term debt total 21782.00M 24523.00M 27978.00M 22056.00M 22470.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 1468.00M 6815.00M -13182.00000M -2226.00000M -5591.00000M
Change to liabilities -48.00000M -21.00000M -324.00000M 553.00M 252.00M
Total cashflows from investing activities 1468.00M 4208.00M -13182.00000M -2226.00000M -5591.00000M
Net borrowings -2559.00000M -5986.00000M 7072.00M -4957.00000M 4177.00M
Total cash from financing activities -20562.00000M -16264.00000M -2208.00000M -13627.00000M -4244.00000M
Change to operating activities -421.00000M -549.00000M -1998.00000M 84.00M 617.00M
Net income 6955.00M 24018.00M 8071.00M 7147.00M 12614.00M
Change in cash -4890.00000M 2749.00M -1454.00000M -2159.00000M 4411.00M
Begin period cash flow 12407.00M 9658.00M 11112.00M 13271.00M 8860.00M
End period cash flow 7517.00M 12407.00M 9658.00M 11112.00M 13271.00M
Total cash from operating activities 14236.00M 15071.00M 13650.00M 13625.00M 14272.00M
Issuance of capital stock - - - - -
Depreciation 7181.00M 6113.00M 6464.00M 5826.00M 6892.00M
Other cashflows from investing activities 4139.00M -57.00000M -186.00000M -1216.00000M -1031.00000M
Dividends paid 7506.00M 7368.00M 6987.00M 6645.00M 6966.00M
Change to inventory -830.00000M 81.00M -543.00000M -382.00000M -533.00000M
Change to account receivables -589.00000M -389.00000M 137.00M -980.00000M -569.00000M
Sale purchase of stock -10652.00000M -3057.00000M -2842.00000M -5533.00000M -2036.00000M
Other cashflows from financing activities 466.00M 94.00M -149.00000M 50.00M -113.00000M
Change to netincome 3721.00M -13501.00000M 2756.00M -2070.00000M -3488.00000M
Capital expenditures 2671.00M 2971.00M 2585.00M 2257.00M 3355.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1003.00000M 241.00M -291.00000M 199.00M 499.00M
Stock based compensation 823.00M 736.00M 738.00M 758.00M 759.00M
Other non cash items -1136.00000M -18156.00000M -3139.00000M -2098.00000M -7713.00000M
Free cash flow 11565.00M 12100.00M 11065.00M 11368.00M 10917.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NVS
Novartis AG ADR		 -1.2 0.74% 161.59 25.58 13.79 3.75 5.23 3.96 11.07
LLY
Eli Lilly and Company		 -7.04 0.70% 1001.35 78.14 31.95 16.34 45.83 16.65 54.36
JNJ
Johnson & Johnson		 1.12 0.46% 243.71 29.17 14.33 3.74 5.18 3.80 15.22
ABBV
AbbVie Inc		 -0.44 0.19% 227.01 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc		 -0.02 0.02% 117.09 59.83 12.33 4.50 6.47 4.94 23.79

Reports Covered

Stock Research & News

View All

Profile

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Novartis AG ADR

Lichtstrasse 35, Basel, Switzerland, 4056

Key Executives

Name Title Year Born
Dr. Vasant Narasimhan Chief Exec. Officer 1976
Mr. Harry Kirsch Chief Financial Officer 1965
Dr. Klaus Moosmayer Ph.D. Chief Ethics, Risk & Compliance Officer 1968
Ms. Karen L. Hale Chief Legal Officer 1968
Dr. Robert Kowalski Pharm.D. Chief People & Organization Officer 1968
Mr. Steffen Lang Ph.D. Pres of Operations 1967
Ms. Marie-France Tschudin Pres of Innovative Medicines International & Chief Commercial Officer 1971
Mr. Richard Saynor Chief Exec. Officer of Sandoz 1967
Paul Penepent Head of Group Financial Reporting and Accounting NA
Dr. Samir Shah M.D. Global Head of Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.